Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

View Full Paper
Ask AI
Bookmark
Share

Authors

IKIoannis KostopoulosMDMattia D’AgostinoDŽDavid Žihala

Discussion

Loading...

Member takes

Overview

Analysis reveals undetectable circulating tumor cells linked to improved prognostic value and progression free survival in multiple myeloma.

Key Points

  • Undetectable circulating tumor cells correlate with significantly improved progression free survival for patients.
  • Among newly diagnosed multiple myeloma patients, 10% had undetectable circulating tumor cells before treatment.
  • Assessment via next-generation flow and exome sequencing identified distinct clinical features and molecular alterations.
  • Highlights need for recognition of undetectable circulating tumor cells as an important prognostic factor.

Cite This Study

Kostopoulos et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08ahttps://doi.org/10.1182/blood-2025-366
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant2025
  2. 2Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.2025 · 2 citations
  3. 3Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden2025
  4. 4Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells2025 · 1 citations
  5. 5Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025